These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 19087359)
21. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Ganey PE; Sprugel KH; White SM; Wagner JG; Roth RA Am J Physiol; 1988 Nov; 255(5 Pt 2):H1165-72. PubMed ID: 3189578 [TBL] [Abstract][Full Text] [Related]
22. Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression. Zhu R; Bi L; Kong H; Xie W; Hong Y; Wang H Int J Clin Exp Pathol; 2015; 8(10):12169-76. PubMed ID: 26722401 [TBL] [Abstract][Full Text] [Related]
23. Early indications of monocrotaline pyrrole-induced lung injury in rats. Schultze AE; Wagner JG; White SM; Roth RA Toxicol Appl Pharmacol; 1991 Jun; 109(1):41-50. PubMed ID: 2038748 [TBL] [Abstract][Full Text] [Related]
24. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924 [TBL] [Abstract][Full Text] [Related]
25. Monokine-induced lung injury in rats: similarities to monocrotaline-induced pneumotoxicity. Gillespie MN; Olson JW; Hennig B; Cohen DA; McClain CJ; Goldblum SE Toxicol Appl Pharmacol; 1989 Mar; 98(1):134-43. PubMed ID: 2494779 [TBL] [Abstract][Full Text] [Related]
26. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole. Schultze AE; Roth RA Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795 [TBL] [Abstract][Full Text] [Related]
27. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension. Hilliker KS; Bell TG; Lorimer D; Roth RA Am J Physiol; 1984 Jun; 246(6 Pt 2):H747-53. PubMed ID: 6742140 [TBL] [Abstract][Full Text] [Related]
28. Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension. Gillespie MN; Goldblum SE; Cohen DA; McClain CJ Proc Soc Exp Biol Med; 1988 Jan; 187(1):26-32. PubMed ID: 3124119 [TBL] [Abstract][Full Text] [Related]
29. Pathophysiology of infantile pulmonary arterial hypertension induced by monocrotaline. Dias-Neto M; Luísa-Neves A; Pinho S; Gonçalves N; Mendes M; Eloy C; Lopes JM; Gonçalves D; Ferreira-Pinto M; Leite-Moreira AF; Henriques-Coelho T Pediatr Cardiol; 2015 Jun; 36(5):1000-13. PubMed ID: 25608696 [TBL] [Abstract][Full Text] [Related]
30. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration. Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824 [TBL] [Abstract][Full Text] [Related]
31. Exaggerated pulmonary hypertension with monocrotaline in rats susceptible to chronic mountain sickness. Colice GL; Hill N; Lee YJ; Du H; Klinger J; Leiter JC; Ou LC J Appl Physiol (1985); 1997 Jul; 83(1):25-31. PubMed ID: 9216940 [TBL] [Abstract][Full Text] [Related]
32. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats. Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725 [TBL] [Abstract][Full Text] [Related]